Shares of Finch Therapeutics Group, Inc. (NASDAQ:FNCH – Get Free Report) dropped 3.3% on Thursday . The company traded as low as $10.36 and last traded at $10.36. Approximately 3,774 shares were traded during trading, a decline of 85% from the average daily volume of 25,355 shares. The stock had previously closed at $10.71.
Finch Therapeutics Group Stock Performance
The stock has a market cap of $16.64 million, a P/E ratio of -1.17 and a beta of 1.29. The company has a 50-day simple moving average of $11.75 and a 200-day simple moving average of $8.24.
Finch Therapeutics Group Company Profile
Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates.
Featured Stories
- Five stocks we like better than Finch Therapeutics Group
- How to Calculate Options Profits
- Micron Stock Under $100: Seize the AI-Driven Upside
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- AI’s Next Big Winners: 3 Small-Cap Stocks to Watch in 2025
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- SolarEdge Stock Climbs Back: Goldman Sachs Sees 40% Upside
Receive News & Ratings for Finch Therapeutics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Finch Therapeutics Group and related companies with MarketBeat.com's FREE daily email newsletter.
